0K2H Stock Chart & Stats
$0.67
-$0.33(-29.20%)
At close: 4:00 PM EDT
$0.67
-$0.33(-29.20%)
Day’s Range― - ―
52-Week Range$0.24 - $17.27
Previous CloseN/A
Volume44.88K
Average Volume (3M)23.90K
Market Cap
$11.72M
Enterprise Value$8.88
Total Cash (Recent Filing)$7.26M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.13
Shares Outstanding19,477,380
10 Day Avg. Volume33,499
30 Day Avg. Volume23,904
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside1691.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial ExecutionClosing enrollment in the pivotal MIRACLE trial represents meaningful execution progress and preserves a defined near-term clinical milestone. The broader cohort should provide efficacy insight across key AML patient groups, potentially supporting dose selection and later regulatory or partnering discussions.
Annamycin Cardiac SafetyThe peer-reviewed cardiac-safety findings could strengthen Annamycin’s differentiation within the anthracycline class, where cardiotoxicity can constrain use. Consistent safety observations across five trials and high cumulative exposure support continued development and may improve the candidate’s clinical positioning.
Long-dated Intellectual PropertyPatent protection through 2040 provides a potentially durable exclusivity foundation for Annamycin formulations and future lung-focused indications. Combined with ongoing clinical development, the protected technology may help preserve strategic differentiation and support commercial or partnering value if efficacy is validated.
Bears Say
Pre-commercial Operating ModelMoleculin remains pre-commercial, so its research and clinical programs are not yet funded by recurring product sales. Persistent losses without offsetting revenue leave profitability dependent on future clinical success, commercialization, licensing, or additional financing rather than established operating earnings.
Persistent Cash Burn And Financing DependenceConsistently negative operating and free cash flow show that Moleculin lacks self-funding capacity while advancing expensive clinical programs. Continued reliance on equity or other external capital can constrain strategic flexibility and expose shareholders to dilution as development spending continues.
Nasdaq Listing UncertaintyThe Nasdaq minimum-bid deficiency creates a structural financing and market-access risk beyond ordinary trading volatility. If the hearing process does not restore compliance, delisting could reduce investor access, complicate future capital raising, and weaken the company’s financial flexibility during development.
Moleculin Biotech News
0K2H FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest share price was $0.24 and its highest was $17.27 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $11.72M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 171 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.553 by $0.153.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 19,477,380 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.553. Following the earnings report the stock price went up 13.417%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in GB:0K2H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
0K2H Stock 12 Month Forecast
Average Price Target
$12.00
▲(1691.04% Upside)